Evolent Health Inc (NYSE:EVH) – Investment analysts at William Blair issued their Q3 2018 earnings per share estimates for shares of Evolent Health in a research report issued to clients and investors on Wednesday. William Blair analyst R. Daniels forecasts that the technology company will post earnings per share of ($0.01) for the quarter. William Blair also issued estimates for Evolent Health’s Q4 2018 earnings at $0.01 EPS.
Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The company had revenue of $107.90 million during the quarter, compared to analyst estimates of $104.49 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. The firm’s revenue for the quarter was up 79.2% compared to the same quarter last year.
Evolent Health (NYSE:EVH) traded down $0.15 during trading hours on Friday, reaching $13.25. 892,400 shares of the company were exchanged, compared to its average volume of 1,240,567. Evolent Health has a 52 week low of $10.30 and a 52 week high of $27.50. The stock has a market capitalization of $1,020.00 and a price-to-earnings ratio of -11.62. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11.
Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of Evolent Health by 7.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock valued at $137,857,000 after purchasing an additional 379,185 shares during the last quarter. Stifel Financial Corp acquired a new position in Evolent Health in the 2nd quarter worth approximately $425,000. Kornitzer Capital Management Inc. KS acquired a new position in Evolent Health in the 3rd quarter worth approximately $14,258,000. Edmond DE Rothschild Holding S.A. increased its holdings in Evolent Health by 6.9% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 387,000 shares of the technology company’s stock worth $9,810,000 after buying an additional 25,000 shares during the period. Finally, Alyeska Investment Group L.P. increased its holdings in Evolent Health by 393.1% in the 3rd quarter. Alyeska Investment Group L.P. now owns 250,000 shares of the technology company’s stock worth $4,450,000 after buying an additional 199,300 shares during the period. 95.38% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Evolent Health Inc Forecasted to Post Q3 2018 Earnings of ($0.01) Per Share (EVH)” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/05/evolent-health-inc-forecasted-to-post-q3-2018-earnings-of-0-01-per-share-evh.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.